Fig. 3.

FluA DMAb protects mice from diverse lethal influenza A challenges. BALB/c mice were treated with FluA DMAb plasmid DNA (closed symbols) 4–5 days prior to intranasal infection with A/California/7/2009 H1N1 (a–c) or re-assorted rA/HongKong/8/68 × PR8 H3N1 (d–f). 1 day prior to infection, separate mice received 0.03–1 mg/kg FluA protein monoclonal antibody i.p. (open symbols). Mice treated with 300 μg irrelevant DMAb (DVSF-3) or 1 mg/kg non-specific protein monoclonal antibody (R347) served as controls. a, d Human IgG in mouse sera at the time of influenza infection. Dotted line indicates LOD. (a n = 10 animals, d n = 5 animals per group, mean ± SD). b, e Kaplan–Meier survival curves of BALB/c mice challenged with influenza A (n = 10 animals per group, *p ≤ 0.0001 FluA DMAb versus Control DMAb). c, f Weight of BALB/c mice following influenza A challenge. Dotted line indicates 25% maximum weight loss. (n = 10 animals per group, mean ± SEM)